ProQR Therapeutics NV opened higher at $1.35, compared with its previous close of $1.26. In the last trading session, the stock traded between $1.25 and $1.40. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in ProQR Therapeutics NV is now worth
$ 17.33
Resulting in a loss of
$ 82.67 (82.67%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.10 (+7.70%)
Day High
$1.40
Day Low
$1.25
Day Open
$1.35
Prev Close
$1.26
Volume
7,68,791
1W Return
-3.90%
1M Return
-15.82%
3M Return
-29.21%
6M Return
-15.71%
1Y Return
-37.18%
Fundamentals
Market Cap ($ Mn)
187
PE Ratio
-
PB Ratio
5.61
PEG Ratio
-
ROE
-80.71%
ROCE
-41.65%
EPS (TTM)
$-0.06
Investment Returns
1 Week
-3.90%
1 Month
-15.82%
3 Months
-29.21%
6 Months
-15.71%
9 Months
-4.44%
Financials
Quarterly
All values in $ Mn
4.5
Mar 25
3.8
Jun 25
2.9
Sep 25
4.7
Dec 25
2.0
Mar 26
8.8
Jun 26
Updates
12Nov
ProQR holds €103 million cash, extends runway to mid-2028
Cash and cash equivalents reached €103 million, supporting runway into mid-2028. Net loss widened to €12.4 million in Q3 2026 from €11.0 million in Q3 2025. R&D expenses rose to €14.3 million from €11.1 million year-on-year. Initial AX-0811 Phase 1 target engagement data expected in early January 2027.
Today
20Aug
B of A Securities initiates coverage on ProQR Therapeutics with Buy rating
B of A Securities analyst Alec Stranahan initiates coverage on ProQR Therapeutics (NASDAQ: PRQR) with a Buy rating. The firm establishes a price target of $8, marking its first coverage of the biotechnology firm.
2mo ago
13Aug
ProQR Q2 Results: Sales up 135% YoY to $10.18M, EPS beats
ProQR Therapeutics delivered a strong Q2 performance with sales of $10.183M, beating estimates by 83% and rising 135% YoY. EPS of $(0.09) beat the $(0.14) estimate, though losses widened 25% compared to the prior year period.
3mo ago
4Aug
ProQR CEO Daniel De Boer buys 200,000 shares at $1.77
ProQR Therapeutics CEO Daniel De Boer bought 200,000 shares at $1.77 each, raising his direct holdings to 500,000. The SEC Form 4 filing highlights increased insider confidence in the biotech firm's prospects.
3mo ago
7Jul
ProQR Therapeutics files prospectus for 3.03M share offering
ProQR Therapeutics filed a prospectus for an offering of 3.03M ordinary shares on behalf of a selling shareholder. The company will not receive any proceeds from the sale. The offering is subject to market conditions.
4mo ago
29Jun
Evercore ISI raises ProQR target to $6, maintains Outperform
Evercore ISI Group analyst Gavin Clark-Gartner maintained an Outperform rating on ProQR Therapeutics and raised the price target to $6 from $5.
